Genmab Announces Record-Breaking Net Sales of USD 11,670 Million for DARZALEX in 2024
Genmab A/S, a leading creator of antibody therapeutics, recently announced impressive net sales figures for DARZALEX (daratumumab) in 2024. DARZALEX, a monoclonal antibody therapy developed in collaboration with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, reported worldwide net sales of USD 11,670 million.
Sales Breakdown
The net sales included USD 6,588 million from the U.S. market and USD 5,082 million from the rest of the world. The U.S. sales were primarily driven by the subcutaneous (SC) formulation of DARZALEX, sold under the tradename DARZALEX FASPRO in the U.S., which accounted for approximately 57% of the total net sales.
Impact on Genmab
This significant sales achievement represents a major milestone for Genmab, as it underscores the strong market demand for DARZALEX and reinforces the company’s position as a leader in antibody therapeutics. Genmab will continue to receive royalties on the worldwide net sales from Janssen Biotech, providing a steady revenue stream and contributing to the company’s growth.
Impact on Patients and the World
The success of DARZALEX has far-reaching implications for patients suffering from various forms of multiple myeloma and light chain (AL) amyloidosis. These diseases are characterized by uncontrolled production of abnormal proteins, leading to debilitating symptoms and potentially life-threatening complications. DARZALEX is a first-in-class therapy that specifically targets CD38, a protein found on the surface of multiple myeloma cells.
By binding to CD38, DARZALEX helps the body’s immune system to destroy these cancer cells. The availability of the subcutaneous formulation offers greater convenience and flexibility for patients, as it allows for self-administration at home instead of frequent visits to healthcare facilities for intravenous infusions. This not only enhances the patient experience but also reduces healthcare costs.
Moreover, the success of DARZALEX is a testament to the potential of antibody therapeutics in addressing unmet medical needs and improving patient outcomes. It is expected that this momentum will continue, as Genmab and Janssen Biotech continue to explore new indications and expand the use of DARZALEX in various forms of cancer.
Conclusion
Genmab’s record-breaking net sales of USD 11,670 million for DARZALEX in 2024 is a significant achievement that underscores the strong market demand for this innovative antibody therapy. The success of DARZALEX not only benefits Genmab through ongoing royalty payments but also contributes to the advancement of patient care by offering a more convenient and effective treatment option for multiple myeloma and light chain (AL) amyloidosis patients. As Genmab and Janssen Biotech continue to explore new indications and expand the use of DARZALEX, the impact on patients and the world is expected to be profound.
- Genmab reported worldwide net sales of USD 11,670 million for DARZALEX in 2024.
- Net sales included USD 6,588 million from the U.S. and USD 5,082 million from the rest of the world.
- The success of DARZALEX offers greater convenience and flexibility for patients through the availability of the subcutaneous formulation.
- The impact of DARZALEX extends beyond Genmab, as it contributes to the advancement of patient care and the potential for new indications in various forms of cancer.
